Cooley advised Vaccine Company, a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, on its agreement to be acquired by Eli Lilly for up to $1.5 billion.
Vaccine Company to be Acquired by Eli Lilly for up to $1.5 Billion